Drug Trial Radar · NCT03941262
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
Last checked: Nov 19, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Jul 15, 2019
Primary completion
Feb 17, 2023
Study completion Feb 17, 2023
Sponsor
- Lead sponsor
- NKGen Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent and in combination with avelumab or pembrolizumab, for the treatment of subjects with advanced and/or metastatic refractory cancer that has failed three or more prior lines of conventional standard of care therapy.
Conditions
- Refractory Cancer
- Metastatic Cancer
- Recurrent Cancer
- Unresectable Carcinoma
- Solid Tumor, Adult
- Advanced Cancer
- Advanced Solid Tumor
Interventions
SNK01Biological
Patient-specific ex vivo expanded autologous natural killer cells
AvelumabDrug
Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1).
PembrolizumabDrug
Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1).
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety profileTime frame: Up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sarcoma Oncology Research Center
Santa Monica, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.